RT Journal Article ID 68810b5049b03aa2 A1 Hong, Mengying A1 Tang, Kejun A1 Qian, Jing A1 Deng, Hongyu A1 Zeng, Musheng A1 Zheng, Shu A1 Ding, Kefeng A1 Du, Yushen A1 Sun, Ren T1 Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma JF Critical Reviews™ in Oncogenesis JO CRO YR 2018 FD 2018-09-04 VO 23 IS 3-4 SP 219 OP 234 K1 EBV K1 nasopharyngeal carcinoma K1 immunotherapy AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is one of the most common head and neck malignancies in southern China and Southeast Asia. Unfortunately, 70% of NPC patients have locally advanced disease at the first diagnosis. Radiotherapy alone and concurrent chemoradiotherapy are important treatment approaches for NPC, but they have a limited effect on patients with locally advanced or distantly metastatic disease. 1–5 Nevertheless, the unique immune environment of the EBV-associated NPC provides rational targets for immunotherapy. Diverse types of immunotherapies are actively being studied, including adoptive immunotherapy, therapeutic vaccines, immune checkpoint inhibitors, lytic-induction therapy, and viral immunotherapy. Specifically, adoptive immunotherapy with lymphocyte infusion was well tolerated and effective in 71.4% of patients combined with first-line chemotherapy. Several therapeutic vaccines and PD-1/PD-L1 pathway checkpoint inhibitors have shown promising clinic outcomes at phase I/II clinical trials. Moreover, EBV-lytic inducing therapy and viral immunotherapy for NPC are also being investigated. In this review, we summarized the current status, advantages, and disadvantages of each immunotherapy for EBV-associated NPC, which may shed light on developing safer and more effective treatment modalities in the future. PB Begell House LK https://www.dl.begellhouse.com/journals/439f422d0783386a,514990c96a5e2eab,68810b5049b03aa2.html